Monitor for enrollment updates and eventual Phase 2b top-line data in 2027. No near-term financial catalysts; stock movement likely driven by broader sector sentiment and trial execution risk.
Price Chart
Executive Summary
Evommune announced initiation of a Phase 2b clinical trial for EVO756, an oral MRGPRX2 antagonist, for migraine prophylaxis. The 330-patient, placebo-controlled, dose-ranging study is underway with top-line data expected in 2027. This is a pipeline expansion into a large market but provides no financial data or near-term catalyst.
Key Facts
- First patient dosed in Phase 2b trial of EVO756 for migraine prophylaxis
- Global randomized double-blind placebo-controlled dose-ranging study with ~330 patients
- Daily doses up to 100 mg over 12 weeks
- Primary endpoint: mean change in monthly migraine days (MMD)
- Top-line data expected in 2027
- EVO756 is a first-in-class oral small molecule MRGPRX2 antagonist targeting three neuropeptides (PACAP, VIP, Substance P)
Financial Impact
No financial data in filing; pipeline value depends on successful Phase 2b readout in a large migraine market (40M+ US patients). Pre-revenue clinical-stage company.
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data
- Enrollment delays or higher-than-expected dropout rates
- Competition from existing CGRP inhibitors and other migraine therapies
- Cash burn for ongoing trials without revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-324972 |
| Document: evmn-ex99_1.htm | 0001193125-26-324972 |
| Document: 0001193125-26-324972-index-headers.html | 0001193125-26-324972 |
| Document: 0001193125-26-324972-index.html | 0001193125-26-324972 |
| Document: 0001193125-26-324972.txt | 0001193125-26-324972 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $7.21 | awaiting T+60 | — | $5.13 (−28.85%) |
Sep 15, 2026 5w ago | 8-K | $9.99 | awaiting T+60 | — | $5.13 (−48.65%) |
Jul 30, 2026 12w ago | 8-K | $11.35 $5.10 | ▼ −55.07% | ▼ −57.53% | $5.13 (−54.80%) |
Jul 10, 2026 15w ago | Insider Cluster | $12.10 $6.61 | ▼ −45.37% | ▼ −49.37% | $5.13 (−57.60%) |
Jun 29, 2026 17w ago | 8-K | $15.05 $9.60 | ▲ +36.21% | ▲ +40.60% | $5.13 (+65.91%) |
Jun 24, 2026 17w ago | Insider Cluster | $24.13 $9.65 | ▼ −60.01% | ▼ −63.74% | $5.13 (−78.74%) |
Jun 3, 2026 20w ago | Insider Cluster | $20.69 $13.23 | ▲ +36.06% | ▲ +37.94% | $5.13 (+75.21%) |
Jun 2, 2026 20w ago | 144 | $19.73 $13.48 | ▼ −31.68% | ▼ −34.18% | $5.13 (−74.00%) |
Jun 1, 2026 21w ago | Insider Cluster | $19.82 $14.11 | ▼ −28.81% | ▼ −29.93% | $5.13 (−74.12%) |
May 28, 2026 21w ago | 144 | $23.23 $13.67 | ▲ +41.15% | ▲ +42.34% | $5.13 (+77.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers